About Traws Pharma Inc
Ticker
info
TRAW
Trading on
info
NASDAQ
ISIN
info
US68232V8845
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Iain D. Dukes DPHIL, M.A., Ph.D.
Headquarters
info
12 Penns Trail, Newtown, PA, United States, 18940
Employees
info
6
Website
info
trawspharma.com
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Metrics
BasicAdvanced
Market cap
info
$8.6M
P/E ratio
info
-
EPS
info
-$27.20
Dividend Yield
info
0.00%
Beta
info
1.47
Forward P/E ratio
info
0
EBIDTA
info
$-24.9M
Ex dividend date
info
-
Price & volume
Market cap
info
$8.6M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
37.75
Price to book
info
1.43
Earnings
EPS
info
-$27.20
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-24.9M
Revenues (TTM)
info
$0.2M
Revenues per share (TTM)
info
$0.07
Technicals
Beta
info
1.47
52-week High
info
$15.00
52-week Low
info
$0.97
50-day moving average
info
$1.54
200-day moving average
info
$3.80
Short ratio
info
1.42
Short %
info
4.06%
Management effectiveness
ROE (TTM)
info
-2,331.25%
ROA (TTM)
info
-83.59%
Profit margin
info
0.00%
Gross profit margin
info
$0.2M
Operating margin
info
-9,128.07%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
1.80%
Share stats
Outstanding Shares
info
5.6M
Float
info
3.8M
Insiders %
info
18.86%
Institutions %
info
31.23%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$6.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$4.87
-$6.25
22.16%
Q2 • 24Beat
-$8.81
-$6.25
-41.03%
Q3 • 24Missed
$26.60
-$0.25
10,740.00%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0.1M
$-29.9M
-53,432.14%
Q4 • 24
$0.1M
$21.5M
37,701.75%
Q1 • 25
1.79%
-171.82%
-170.56%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$25M
$56.6M
226.71%
Q4 • 24
$19.1M
$13.1M
68.53%
Q1 • 25
-23.63%
-76.92%
-69.77%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-4M
$0M
$20M
$-4M
Q4 • 24
$-5.4M
-
$0M
$-5.4M
Q1 • 25
34.58%
-
-99.93%
34.58%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Traws Pharma Inc share?
Collapse

Traws Pharma Inc shares are currently traded for undefined per share.

How many shares does Traws Pharma Inc have?
Collapse

Traws Pharma Inc currently has 5.6M shares.

Does Traws Pharma Inc pay dividends?
Collapse

No, Traws Pharma Inc doesn't pay dividends.

What is Traws Pharma Inc 52 week high?
Collapse

Traws Pharma Inc 52 week high is $15.00.

What is Traws Pharma Inc 52 week low?
Collapse

Traws Pharma Inc 52 week low is $0.97.

What is the 200-day moving average of Traws Pharma Inc?
Collapse

Traws Pharma Inc 200-day moving average is $3.80.

Who is Traws Pharma Inc CEO?
Collapse

The CEO of Traws Pharma Inc is Dr. Iain D. Dukes DPHIL, M.A., Ph.D..

How many employees Traws Pharma Inc has?
Collapse

Traws Pharma Inc has 6 employees.

What is the market cap of Traws Pharma Inc?
Collapse

The market cap of Traws Pharma Inc is $8.6M.

What is the P/E of Traws Pharma Inc?
Collapse

The current P/E of Traws Pharma Inc is null.

What is the EPS of Traws Pharma Inc?
Collapse

The EPS of Traws Pharma Inc is -$27.20.

What is the PEG Ratio of Traws Pharma Inc?
Collapse

The PEG Ratio of Traws Pharma Inc is null.

What do analysts say about Traws Pharma Inc?
Collapse

According to the analysts Traws Pharma Inc is considered a buy.